EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and n… Read more
EVGEN PHARMA PLC LS-0025 (8EV) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EVGEN PHARMA PLC LS-0025 (8EV) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EVGEN PHARMA PLC LS-0025 - Net Assets Trend (None–None)
This chart illustrates how EVGEN PHARMA PLC LS-0025's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EVGEN PHARMA PLC LS-0025 (None–None)
The table below shows the annual net assets of EVGEN PHARMA PLC LS-0025 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EVGEN PHARMA PLC LS-0025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EVGEN PHARMA PLC LS-0025 Competitors by Market Cap
The table below lists competitors of EVGEN PHARMA PLC LS-0025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elray Resources Inc
PINK:ELRA
|
$651.36K |
|
Nykredit Invest Danske aktier Akk
CO:NYIDAA
|
$651.64K |
|
Sifi CJ Logistic SA
RO:CACU
|
$651.95K |
|
LAM RESEARCH CORP - Dusseldorf Stock Exchang
DU:LAR
|
$652.09K |
|
HENRY SCHEIN - Dusseldorf Stock Exchang
DU:HS2
|
$650.81K |
|
Green Stream Holdings Inc
PINK:GSFI
|
$650.80K |
|
Barratt Redrow plc
LSE:BTRW
|
$650.42K |
|
HEINEKEN (HNK1.SG)
STU:HNK1
|
$649.15K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EVGEN PHARMA PLC LS-0025's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EVGEN PHARMA PLC LS-0025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EVGEN PHARMA PLC LS-0025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EVGEN PHARMA PLC LS-0025's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EVGEN PHARMA PLC LS-0025 (8EV) | €- | N/A | N/A | $650.99K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |